News headlines about Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) have trended somewhat positive this week, Accern Sentiment reports. Accern ranks the sentiment of media coverage by analyzing more than 20 million blog and news sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Aurinia Pharmaceuticals earned a news sentiment score of 0.21 on Accern’s scale. Accern also gave media coverage about the biotechnology company an impact score of 45.4674188044365 out of 100, meaning that recent media coverage is somewhat unlikely to have an effect on the company’s share price in the next few days.

These are some of the news headlines that may have impacted Accern’s analysis:

Aurinia Pharmaceuticals (AUPH) traded up 0.92% during mid-day trading on Friday, reaching $6.56. The company’s stock had a trading volume of 1,378,159 shares. The firm’s 50 day moving average is $6.30 and its 200-day moving average is $6.62. Aurinia Pharmaceuticals has a one year low of $2.02 and a one year high of $10.54. The stock’s market cap is $350.49 million.

Aurinia Pharmaceuticals (NASDAQ:AUPH) (TSE:AUP) last released its quarterly earnings data on Thursday, August 10th. The biotechnology company reported ($0.03) earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of ($0.13) by $0.10. Aurinia Pharmaceuticals had a negative net margin of 16,648.93% and a negative return on equity of 28.61%. The firm had revenue of $0.33 million for the quarter, compared to the consensus estimate of $0.06 million. Equities analysts expect that Aurinia Pharmaceuticals will post ($0.94) earnings per share for the current fiscal year.

AUPH has been the topic of several recent analyst reports. Vetr cut Aurinia Pharmaceuticals from a “strong-buy” rating to a “buy” rating and set a $6.74 target price on the stock. in a research note on Monday, July 31st. Zacks Investment Research raised Aurinia Pharmaceuticals from a “hold” rating to a “buy” rating and set a $7.00 price objective on the stock in a research report on Tuesday, August 15th. BidaskClub cut Aurinia Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Friday, July 28th. Cantor Fitzgerald set a $14.00 price objective on Aurinia Pharmaceuticals and gave the company a “buy” rating in a research report on Friday, August 11th. Finally, Seaport Global Securities started coverage on Aurinia Pharmaceuticals in a research report on Friday. They set a “buy” rating and a $10.00 price objective on the stock. One analyst has rated the stock with a sell rating, nine have issued a buy rating and one has given a strong buy rating to the company. The stock has an average rating of “Buy” and an average target price of $9.82.

TRADEMARK VIOLATION WARNING: This article was posted by Watch List News and is the sole property of of Watch List News. If you are accessing this article on another domain, it was copied illegally and reposted in violation of U.S. & international copyright and trademark legislation. The legal version of this article can be viewed at https://www.watchlistnews.com/aurinia-pharmaceuticals-auph-receives-media-sentiment-rating-of-0-21/1613500.html.

Aurinia Pharmaceuticals Company Profile

Aurinia Pharmaceuticals Inc is a Canada-based clinical-stage biopharmaceutical company operating in the field of nephrology and autoimmunity. The Company’s primary business is the development of a therapeutic drug to treat autoimmune diseases, in particular lupus nephritis (LN). It is focused on the development of its lead compound voclosporin, a therapeutic immunomodulating drug candidate, which is a second-generation calcineurin inhibitors (CNI) to treat patients afflicted with LN.

Insider Buying and Selling by Quarter for Aurinia Pharmaceuticals (NASDAQ:AUPH)

Receive News & Ratings for Aurinia Pharmaceuticals Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aurinia Pharmaceuticals Inc and related companies with Analyst Ratings Network's FREE daily email newsletter.